Skip to main content

Editas Medicine, Inc 8-K, filed Nov 9, 2026

Editas Medicine, Inc. (EDIT)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Editas Medicine, Inc filed this 8-K on November 9, 2026.

Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits